Article
Oncology
Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Hui-Yi Lin, Po-Yu Huang, Chia-Ho Cheng, Heng-Yuan Tung, Zhide Fang, Anders E. Berglund, Ann Chen, Jennifer French-Kwawu, Darian Harris, Julio Pow-Sang, Kosj Yamoah, John L. Cleveland, Shivanshu Awasthi, Robert J. Rounbehler, Travis Gerke, Jasreman Dhillon, Rosalind Eeles, Zsofia Kote-Jarai, Kenneth Muir, Johanna Schleutker, Nora Pashayan, David E. Neal, Sune F. Nielsen, Borge G. Nordestgaard, Henrik Gronberg, Fredrik Wiklund, Graham G. Giles, Christopher A. Haiman, Ruth C. Travis, Janet L. Stanford, Adam S. Kibel, Cezary Cybulski, Kay-Tee Khaw, Christiane Maier, Stephen N. Thibodeau, Manuel R. Teixeira, Lisa Cannon-Albright, Hermann Brenner, Radka Kaneva, Hardev Pandha, Srilakshmi Srinivasan, Judith Clements, Jyotsna Batra, Jong Y. Park
Summary: The study identified SNP-SNP interactions associated with prostate cancer aggressiveness, with a majority involving the KLK3 gene. Predictions based on a polygenic risk score from 24 SNP pairs showed promising results. The findings suggest that KLK3 SNP interactions may play an important role in PCa aggressiveness.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Tesa Severson, Xintao Qiu, Mohammed Alshalalfa, Martin Sjostrom, David Quigley, Andries Bergman, Henry Long, Felix Feng, Matthew L. Freedman, Wilbert Zwart, Mark M. Pomerantz
Summary: The androgen receptor (AR) plays a fundamental role in prostate pathophysiology and its reprogrammed binding to DNA contributes to prostate tumorigenesis and disease progression. This study identifies genes regulated by AR in different histological contexts and demonstrates the clinical significance of their expression in prostate cancer patients. The research highlights the importance of integrating context-dependent epigenetic data into genetic analyses.
CLINICAL EPIGENETICS
(2022)
Review
Biochemistry & Molecular Biology
Navid Sobhani, Praveen Kumar Neeli, Alberto D'Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi
Summary: Metastatic prostate cancer is the most common cancer in males with a poor prognosis, and many patients develop the AR-V7 variant. AR-V7 acts as a transcription factor in the nucleus, repressing crucial tumor suppressor genes. Anti-AR-V7 drugs show promise for this subset of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Xiaolei Shi, Abderrahman Day, Hannah E. Bergom, Sydney Tape, Sylvan C. Baca, Zoi E. Sychev, Gabrianne Larson, Asha Bozicevich, Justin M. Drake, Nicholas Zorko, Jinhua Wang, Charles J. Ryan, Emmanuel S. Antonarakis, Justin Hwang
Summary: The study identifies B7-H3 as an immune checkpoint overexpressed in prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide-resistant mCRPC cells show increased expression of B7-H3, and it is associated with resistance signaling pathways. The gene network of B7-H3 is strongly correlated with androgen receptor (AR) and its co-factors, suggesting potential therapeutic targets for mCRPC.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Martin K. Bakht, Yasutaka Yamada, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, Joshua A. Korsen, Teja M. Kalidindi, Kei Mizuno, Shin Hye Ahn, Ji-Heui Seo, Maria Mica Garcia, Francesca Khani, Olivier Elemento, Henry W. W. Long, Alain Chaglassian, Nagavarakishore Pillarsetty, Jason S. Lewis, Matthew Freedman, Anthony P. Belanger, Quang-De Nguyen, Himisha Beltran
Summary: Beltran and colleagues explore the regulatory roles of HOXB13 and AR in the heterogeneous expression of PSMA in castration-resistant prostate cancer. They found that PSMA expression is lost in a subset of CRPC patients and is influenced by the microenvironment. The study also identifies HOXB13 as an upstream regulator of PSMA, independent of AR expression. These findings provide insights for the development of PSMA-targeted therapies and complementary biomarkers.
Article
Oncology
Fen Ma, Seiji Arai, Keshan Wang, Carla Calagua, Amanda R. Yuan, Larysa Poluben, Zhongkai Gu, Joshua W. Russo, David J. Einstein, Huihui Ye, Meng Xiao He, Yu Liu, Eliezer Van Allen, Adam G. Sowalsky, Manoj K. Bhasin, Xin Yuan, Steven P. Balk
Summary: This study reveals the importance of Wnt/beta-catenin signaling in prostate cancer, showing its role in stem cell maintenance and invasion. It identifies new effectors and drivers of this pathway in prostate cancer, such as ROR1 and APC genomic loss. The findings suggest that targeting Wnt/beta-catenin signaling may be a potential therapeutic strategy for prostate cancer.
Article
Oncology
Yasutaka Yamada, Himisha Beltran
Summary: The treatment landscape of metastatic prostate cancer has significantly evolved with the approval of new drugs and rapid changes in therapy options for patients. Despite improvements in survival and quality of life, prostate cancer remains a leading cause of cancer death globally. Disease heterogeneity and therapy resistance are significant challenges, with early stages of using molecular biomarkers to guide systemic agent selection and sequencing.
Article
Oncology
Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Summary: AMG 160, a bispecific T-cell engager immuno-oncology therapy targeting PSMA in mCRPC, demonstrates potent antitumor activity in vitro and in vivo. It shows enhanced cytotoxic activity when combined with diagnostic or therapeutic agents such as the PSMA-imaging agent, novel hormonal therapy, and immune checkpoint blockade. Preclinical data supports ongoing clinical evaluation in patients with mCRPC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Li Tang, Qianqian Zhu, Zinian Wang, Clayton M. Shanahan, Jeannette T. Bensen, Elizabeth T. H. Fontham, Gary J. Smith, Elena A. Pop, Gissou Azabdaftari, James L. Mohler, Yue Wu
Summary: The study identified important and different roles of SLCO2A1 and SLCO5A1 in prostate cancer aggressiveness between African Americans and European Americans. This finding highlights the importance of considering racial differences in biomarker studies of prostate cancer, and the need for further investigation into the functions of SLCO2A1 and SLCO5A1 in prostate cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Article
Multidisciplinary Sciences
Zhao Wei, Song Wang, Yaning Xu, Wenzheng Wang, Fraser Soares, Musaddeque Ahmed, Ping Su, Tingting Wang, Elias Orouji, Xin Xu, Yong Zeng, Sujun Chen, Xiaoyu Liu, Tianwei Jia, Zhaojian Liu, Lutao Du, Yunshan Wang, Shaoyong Chen, Chuanxin Wang, Housheng Hansen He, Haiyang Guo
Summary: This study reveals that MYC interacts with CTCF protein and rewires the chromatin architecture in prostate cancer by modifying CTCF-mediated chromatin looping. MYC colocalizes with CTCF at certain genomic sites, enhancing CTCF occupancy and promoting CTCF-mediated chromatin looping, which disrupts the enhancer-promoter loops of genes related to neuroendocrine lineage plasticity.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Tie Zhou, Shengfei Qin, Weidong Xu, Shouyan Tang, Guanghua Chen, Song Li, Jianguo Hou, Xu Gao, Guowei Shi, Zhongquan Sun, Jie Jin, Lijun Chen, Weibing Sun, Ben Liu, Jingen Wang, Qinggui Meng, Dongwen Wang, Zhiquan Hu, Dalin He, Yong Yang, Xishuang Song, Cheng Fu, Yinhuai Wang, Dingwei Ye, Wei Zhang
Summary: This study assessed the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, in men with metastatic castration-resistant prostate cancer (mCRPC). By evaluating various endpoints, it was found that the 200 mg dose group showed the best antitumor activity with manageable safety. Therefore, a daily dose of 200 mg proxalutamide is recommended for future phase 3 trials.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh
Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.
Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ziruoyu Wang, Yanan Li, Wensi Zhao, Shuai Jiang, Yuqi Huang, Jun Hou, Xuelu Zhang, Zhaoyu Zhai, Chen Yang, Jiaqi Wang, Jiying Zhu, Jianbo Pan, Wei Jiang, Zengxia Li, Mingliang Ye, Minjia Tan, Haowen Jiang, Yongjun Dang
Summary: In this study, 35 Chinese PCa primary cell models were established to capture specific characteristics among PCa patients, including gene mutations, mRNA/protein/surface protein distributions, and pharmaceutical responses. AGR2 was identified as a pre-operative prognostic biomarker in PCa through multi-omics analyses. Crizotinib was found to be a selective compound for malignant PCa primary cells. The integrated multi-omics approach provided a comprehensive understanding of PCa biomarkers and pharmacological responses.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hulya Seymen, Baris Esen, Ibrahim Kulac, Murat Aksoy, Zeynep Unal Kabaoglu, Mehmet Onur Demirkol, Yakup Kordan
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Endocrinology & Metabolism
Levent Trabzonlu, Kenneth J. Pienta, Bruce J. Trock, Angelo M. De Marzo, Sarah R. Amend
Summary: This study reveals that the presence and number of nonproliferating polyaneuploid cancer cells (PACCs) are significant prognostic factors for metastasis-free survival in men who underwent radical prostatectomy for intermediate- or high-risk prostate cancer.
Article
Oncology
Harshath Gupta, Hitoshi Inoue, Yasutomo Nakai, Masashi Nakayama, Tracy Jones, Jessica L. Hicks, Balasubramanian Kumar, Meltem Gurel, William G. Nelson, Angelo M. De Marzo, Srinivasan Yegnasubramanian
Summary: GSTP1 is lowly expressed in normal prostate luminal cells but induced in most proliferative inflammatory atrophy (PIA) lesions. It is silenced in prostatic intraepithelial neoplasia (PIN) and prostate adenocarcinoma (CaP) through CpG island promoter hypermethylation. Methylation density progressively increases in precursor lesions, with PIN lesions showing more partial methylation compared to CaP lesions.
CANCER PREVENTION RESEARCH
(2023)
Meeting Abstract
Biochemistry & Molecular Biology
Duygu Aydemir, Ibrahim Kulac, Selcuk Surucu, Ayse Nazli Basak, Nuriye Nuray Ulusu
FREE RADICAL BIOLOGY AND MEDICINE
(2023)
Article
Pathology
Eric Erak, Lia DePaula Oliveira, Adrianna A. Mendes, Oluwademilade Dairo, Onur Ertunc, Ibrahim Kulac, Javier A. Baena-Del Valle, Tracy Jones, Jessica L. Hicks, Stephanie Glavaris, Gunes Guner, Igor Damasceno Vidal, Mark Markowski, Claire de la Calle, Bruce J. Trock, Avaneesh Meena, Uttara Joshi, Chaith Kondragunta, Saikiran Bonthu, Nitin Singhal, Angelo M. De Marzo, Tamara L. Lotan
Summary: Microscopic examination of prostate cancer has not found a consistent association between molecular and morphologic features. However, deep-learning algorithms trained on hematoxylin and eosin (H & E)-stained whole slide images may be better than human eyes at screening for clinically-relevant genomic alterations. These algorithms can identify prostate tumors with ETS-related gene (ERG) fusions or PTEN deletions.
Article
Biochemistry & Molecular Biology
Eugene Shenderov, Angelo M. M. De Marzo, Tamara L. L. Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E. E. Allaf, Carolyn Chapman, Paul A. A. Moore, Francine Chen, Kristina Sorg, Andrew M. M. White, Sarah E. E. Church, Briana Hudson, Paul A. A. Fields, Shaohui Hu, Samuel R. R. Denmeade, Kenneth J. J. Pienta, Christian P. P. Pavlovich, Ashley E. E. Ross, Charles G. G. Drake, Drew M. M. Pardoll, Emmanuel S. S. Antonarakis
Summary: B7-H3-targeting antibody enoblituzumab has shown potential clinical activity and safety in treating high-risk localized prostate cancer.
Article
Pathology
Ozgur Can Eren, Cisel Aydin Mericoz, Emine Bozkurtlar, Pinar Bulutay, Arzu Baygul, Ibrahim Kulac
Summary: This study validates the effectiveness of the Dako ALK assay in detecting ALK rearrangements in lung adenocarcinoma, and suggests that it can be reliably used to identify cases with ALK rearrangement.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Review
Urology & Nephrology
Joakin O. Mori, Isra Elhussin, W. Nathaniel Brennen, Mindy K. Graham, Tamara L. Lotan, Clayton C. Yates, Angelo M. De Marzo, Samuel R. Denmeade, Srinivasan Yegnasubramanian, William G. Nelson, Gerald V. Denis, Elizabeth A. Platz, Alan K. Meeker, Christopher M. Heaphy
Summary: The stromal component of the tumour microenvironment, particularly fibroblasts, plays a crucial role in promoting prostate cancer progression. Cellular senescence and the associated secretory phenotype of senescent cells can contribute to prostate cancer development and resistance to therapy. Targeting senescent cells or modulating their secretory phenotype could be a promising option for preventing and treating prostate cancer.
NATURE REVIEWS UROLOGY
(2023)
Article
Endocrinology & Metabolism
Onur Ertunc, Erica Smearman, Qizhi Zheng, Jessica L. Hicks, Jacqueline A. Brosnan-Cashman, Tracy Jones, Carolina Gomes-Alexandre, Levent Trabzonlu, Alan K. Meeker, Angelo M. De Marzo, Christopher M. Heaphy
Summary: The new chromogenic in situ hybridization (Telo-CISH) method allows visualization and quantification of telomere content in human prostate tissues at single cell resolution, avoiding the cumbersome fluorescent assays. It is compatible with standard immunohistochemistry, allowing simultaneous assessment of cell types and telomere status, aiding in the identification of precancerous lesions in the prostate.
Article
Pathology
Pinar Bulutay, Dogan Vatansever, Cagatay Taskiran, Cisel A. Mericoz, Fatma Tokat, Nilgun Kapucuoglu, Ibrahim Kulac
Summary: Malignant peritoneal mesothelioma (MPM) is a rare tumor type with unclear molecular properties. Anaplastic lymphoma kinase (ALK) gene rearrangement has been found in a subset of MPMs. Low-grade serous carcinomas (LGSCs) have overlapping features with MPMs, causing potential misdiagnosis. We report a case of an 18-year-old women with STRN-ALK-rearranged MPM, presenting with bilateral pelvic masses, papillary morphology, and expression similar to LGSCs. The identification of ALK alteration in MPMs provides a targeted treatment option for these rare tumor types.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY
(2023)
Article
Surgery
Arif Ozkan, Ersin Koseoglu, Abdullah Erdem Canda, Barbaros Erhan Cil, Ibrahim Can Aykanat, Ahmet Furkan Sarikaya, Kayhan Tarim, Ayse Armutlu, Ibrahim Kulac, Erinc Barcin, Fikri Okan Falay, Yakup Kordan, Dilek Ertoy Baydar, Mevlana Derya Balbay, Tarik Esen
Summary: We evaluated and described the impact of prostatic indocyanine green (ICG) injection on extended pelvic lymph node (LN) dissection (ePLND) in robotic-assisted radical prostatectomy (RARP). The study showed that ICG-guided ePLND may assist in detecting and removing metastatic lymph nodes, potentially improving staging and oncologic outcomes in intermediate- and high-risk patients.
JOURNAL OF ROBOTIC SURGERY
(2023)
Review
Clinical Neurology
Didem Oz, Zerrin Yildirim, Ilayda Kiyi, Yagmur Ozbek, Ibrahim Kulac, Gokhan Erkol, Tarik Tihan, Ibrahim Hakan Gurvit, Gorsev Yener
Summary: This study aims to evaluate the level of dementia awareness in Turkish society. The results suggest that dementia is still an unknown concept for both society and healthcare professionals, with many people considering it as a normal part of aging and believing that there is no cure for dementia.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
(2022)
Review
Pathology
Figen Soylemezoglu, Buge Oz, Reyhan Egilmez, Melike Pekmezci, Suheyla Bozkurt, Ayca Ersen Danyeli, Onder Onguru, Ibrahim Kulac, Tarik Tihan
Summary: In our manuscript, we propose a common terminology for the newly adopted WHO classification of the CNS tumors in the Turkish language. We also discuss the applicability of this classification in low and middle income countries and highlight the potential disparities between the global north and south, which may be amplified by the COVID-19 pandemic.
TURKISH JOURNAL OF PATHOLOGY
(2022)
Meeting Abstract
Oncology
Irem Yenidogan, Nesibe Peker, Bera Aygun, Gamze Deveci, Dondu Kirmizi, Fikret Asarcikli, Banu Oflaz Sozmen, Goktug Akyoldas, Ibrahim Kulac, Ihsan Solaroglu, Fatih Erbey, Devrim Gozuacik
PEDIATRIC BLOOD & CANCER
(2022)
Proceedings Paper
Engineering, Biomedical
Hulya Torun, Numan Batur, Buse Bilgin, Omer Tarik Esengur, Kemal Baysal, Ibrahim Kulac, Ihsan Solaroglu, Mehmet Cengiz Onbasli
Summary: Clinical test results of Raman spectroscopy and machine learning-based glioblastoma identification methodology were reported. The study found that Raman spectroscopy can distinguish glioblastoma from white matter tissues, and machine learning classifiers achieved accurate classification.
MULTISCALE IMAGING AND SPECTROSCOPY III
(2022)